A spice master in New York has a new and unusual clientele: people whose sense of taste has gone quiet. They call it “Ozempic tongue.” And an entire corner of the food world is now reorganizing itself around a smaller, duller appetite — one small, intensely flavored plate at a time.
The scale is why chefs are paying attention. GLP-1 drugs — the class of medicines that mute appetite — went from 3% to 11% of Americans in two years, for weight loss alone.
One small plate
Users report two things at once. Smaller appetites, and flatter flavor. Food simply tastes quieter to them.
So the kitchen is adjusting. Bolder spice. Smaller portions. A plate engineered to land in fewer forkfuls, because there will be fewer forkfuls.
One Boston chef put the new order plainly: “One small plate, plus your health.” That is a menu rewriting itself around a prescription.
Home cooks are doing the same math at the grocery store. Less volume, more intensity. The shopping list changes shape before the industry sees it coming.
Spice sellers see it first. Then restaurants. Then the packaged-food giants, who move last, because reformulating a national brand takes years rather than weeks.
The 24-month demand curve
It is a small story with a giant lesson attached. A demand curve — the map of how much people buy at what price — is supposed to move slowly. This one moved in 24 months.
Ask anyone who owned a packaged-food stock how that feels. The behavior underneath the brand changed, and the brand found out last.
Two years is nothing in consumer land. Brands spend longer than that arguing about a label redesign.
Demand curves do not send a warning email before they move. A single drug quietly rewrote the menu, the portion, and the shopping list — in the time it takes to finish a two-year phone contract.
What “safe” really means now
Here is the investing translation. “Defensive consumer staple” — the label for companies selling things people supposedly always buy — quietly stopped being a synonym for “safe.”
The shelf is far less stable than its reputation. If appetite itself can change for 11% of the country in two years, then no snack aisle is a fortress.
The old test for a staple was simple: do people keep buying it in a recession? The new test is harder: do people keep buying it when their appetite itself changes?
That is exactly why the staples we hold in the Capital Wealth Growth Portfolio are chosen for two traits. Pricing power — the ability to charge more without losing the customer. And adaptability — product lines nimble enough to reformulate the plate when the plate shrinks.
When behavior can shift this fast, the moat is adaptability, not shelf space. We underwrite the companies that can change the recipe.
No trade comes out of this story. A lens does. Every consumer holding now gets asked the same question at review time: if the appetite moves again, can you move with it?